These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29314630)

  • 21. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease.
    Petta S; Ciminnisi S; Di Marco V; Cabibi D; Cammà C; Licata A; Marchesini G; Craxì A
    Aliment Pharmacol Ther; 2017 Feb; 45(4):510-518. PubMed ID: 28028821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals.
    Della Pepa G; Vetrani C; Lombardi G; Bozzetto L; Annuzzi G; Rivellese AA
    Nutrients; 2017 Sep; 9(10):. PubMed ID: 28954437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SCCA-IgM as a Potential Biomarker of Non-Alcoholic Fatty Liver Disease in Patients with Obesity, Prediabetes and Diabetes Undergoing Sleeve Gastrectomy.
    Bettini S; Bordigato E; Milan G; Dal Pra' C; Favaretto F; Belligoli A; Sanna M; Serra R; Foletto M; Prevedello L; Busetto L; Fassina G; Vettor R; Fabris R
    Obes Facts; 2019; 12(3):291-306. PubMed ID: 31104052
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vitamin D: a new player in non-alcoholic fatty liver disease?
    Eliades M; Spyrou E
    World J Gastroenterol; 2015 Feb; 21(6):1718-27. PubMed ID: 25684936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic.
    Hassan K; Bhalla V; El Regal ME; A-Kader HH
    World J Gastroenterol; 2014 Sep; 20(34):12082-101. PubMed ID: 25232245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent Insights Into the Regulation of Coagulation and Thrombosis.
    Li X; Sim MMS; Wood JP
    Arterioscler Thromb Vasc Biol; 2020 May; 40(5):e119-e125. PubMed ID: 32320291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development--a potential therapeutic target?
    Dongiovanni P; Rametta R; Meroni M; Valenti L
    Expert Rev Gastroenterol Hepatol; 2016; 10(2):229-42. PubMed ID: 26641143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Swimming, but not vitamin E, ameliorates prothrombotic state and hypofibrinolysis in a rat model of nonalcoholic fatty liver disease.
    Sakr HF; Abbas AM; Haidara MA
    J Basic Clin Physiol Pharmacol; 2018 Jan; 29(1):61-71. PubMed ID: 29161233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse metabolic phenotype of adolescent girls with non-alcoholic fatty liver disease plus polycystic ovary syndrome compared with other girls and boys.
    Ayonrinde OT; Adams LA; Doherty DA; Mori TA; Beilin LJ; Oddy WH; Hickey M; Sloboda DM; Olynyk JK; Hart R
    J Gastroenterol Hepatol; 2016 May; 31(5):980-7. PubMed ID: 26589977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liver fatty acid-binding protein may be a useful marker for non-alcoholic fatty liver disease but obesity is a major concern.
    Tanoglu A; Beyazit Y
    Wien Klin Wochenschr; 2016 Apr; 128(7-8):304. PubMed ID: 26831187
    [No Abstract]   [Full Text] [Related]  

  • 31. Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3.
    Abenavoli L; Masarone M; Peta V; Milic N; Kobyliak N; Rouabhia S; Persico M
    World J Gastroenterol; 2014 Nov; 20(41):15233-40. PubMed ID: 25386071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Non-alcoholic fatty liver disease (NAFLD)].
    Rau M; Weiss J; Geier A
    Dtsch Med Wochenschr; 2015 Jul; 140(14):1051-5. PubMed ID: 26182253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coagulation and anticoagulation in idiopathic pulmonary fibrosis.
    Crooks MG; Hart SP
    Eur Respir Rev; 2015 Sep; 24(137):392-9. PubMed ID: 26324800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assays of fibrin network properties altered by VKAs in atrial fibrillation - importance of using an appropriate coagulation trigger.
    Ząbczyk M; Blombäck M; Majewski J; Karkowski G; Wallen HN; Undas A; He S
    Thromb Haemost; 2015 Apr; 113(4):851-61. PubMed ID: 25518887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk factors and metabolic abnormality of patients with non-alcoholic fatty liver disease: Either non-obese or obese Chinese population.
    Lee SW; Lee TY; Yang SS; Tung CF; Yeh HZ; Chang CS
    Hepatobiliary Pancreat Dis Int; 2018 Feb; 17(1):45-48. PubMed ID: 29428103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2017 Scientific Sessions Sol Sherry Distinguished Lecture in Thrombosis: Factor XI as a Target for New Anticoagulants.
    Weitz JI; Fredenburgh JC
    Arterioscler Thromb Vasc Biol; 2018 Feb; 38(2):304-310. PubMed ID: 29269514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Editors' Choice papers in Thrombosis and Haemostasis.
    Weber C; Lip GY
    Thromb Haemost; 2015 Jan; 113(1):217-20. PubMed ID: 25567474
    [No Abstract]   [Full Text] [Related]  

  • 38. Tortuosity-powered microfluidic device for assessment of thrombosis and antithrombotic therapy in whole blood.
    Luna DJ; R Pandian NK; Mathur T; Bui J; Gadangi P; Kostousov VV; Hui SR; Teruya J; Jain A
    Sci Rep; 2020 Apr; 10(1):5742. PubMed ID: 32238835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coagulation abnormalities and thrombosis in patients with COVID-19.
    Levi M; Thachil J; Iba T; Levy JH
    Lancet Haematol; 2020 Jun; 7(6):e438-e440. PubMed ID: 32407672
    [No Abstract]   [Full Text] [Related]  

  • 40. Independent markers of nonalcoholic fatty liver disease in a gentrifying population-based Chinese cohort.
    Zhou X; Li Y; Zhang X; Guan YY; Puentes Y; Zhang F; Speliotes EK; Ji L
    Diabetes Metab Res Rev; 2019 Jul; 35(5):e3156. PubMed ID: 30892820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.